Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Akiko Moni Miyashita is a seasoned strategy executive and board director with over 25 years of experience spanning healthcare, life sciences, and technology. She currently serves as the Founder of Beacon Hill Strategy Group, a firm she established in October 2024 that advises chief executive officers on strategic and corporate development matters. Her most recent corporate role was as Executive Vice President and Chief Strategy Officer at Valo Health, an AI-enabled biotech company, where she served from May 2019 through September 2024. Earlier in her career, Miyashita held positions at McKinsey & Company, the strategy and innovation consulting firm Innosight, and IBM, building deep expertise in strategy formulation, corporate finance, and business development across the healthcare and technology sectors.
Miyashita's board service includes her appointment as a director of Averin Capital Acquisition Corp. (Nasdaq: ACAA), a Cayman Islands-incorporated special purpose acquisition company that completed a $250 million initial public offering in February 2026. She joined the Averin Capital board effective May 28, 2026, as a member of the first class of directors, with her term set to expire at the company's first annual general meeting. She filed her initial Form 3 statement of beneficial ownership with the SEC on May 29, 2026. In addition to her SPAC role, Miyashita has served as a director of Halozyme Therapeutics Inc. (Nasdaq: HALO), a San Diego-based biopharmaceutical company, since March 24, 2022. Her mailing address on SEC filings is listed as San Diego, California 92130.
Miyashita holds a Master of Business Administration degree from the Daniels College of Business and an undergraduate degree from the Leeds School of Business. Her professional network and public-company affiliations reflect a focus on AI-enabled biotechnology and healthcare innovation, as highlighted in industry commentary surrounding her Averin Capital appointment, which described her as a former Chief Strategy Officer and CEO advisor in the AI-enabled biotech and technology space. She is 70 years of age as of her most recent SEC disclosures.
This record is keyed to SEC CIK 0001607742 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 4 institutional-holder rows on these vehicles, under 3 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.